title: Limited scleroderma with pauci-immune glomerulonephritis in the presence of renal cell carcinoma.
abstract: Connective tissue disorders increase the risk of malignancy; conversely, they may manifest as rheumatological paraneoplastic syndromes due to an underlying malignancy. We describe the case of a patient with limited scleroderma whose rapid disease progression coincided with the discovery of a renal tumor. A woman, age 75 years, presented with a 3-month history of progressive difficulty grasping objects, unsteadiness, dyspnea, xerostomia, xerophthalmia, and significant weight loss. She had a 10-year history of gastroesophageal reflux and Raynaud's phenomenon. Pertinent physical examination findings included facial telangiectasias, bibasilar inspiratory rales, sclerodactyly, and absent pinprick and vibratory sensation in her toes. She also had swelling and tenderness in several metacarpophalangeal and interphalangeal joints and in both ankles. A renal mass was demonstrated on abdominal computed tomography. A left partial nephrectomy was performed, confirming an unclassified type of renal cell carcinoma, along with a focal proliferative crescentic pauci-immune glomerulonephritis. Medical therapy with rituximab, pulse methylprednisolone, and prednisone led to improvement in her symptoms. The patient's presentation is consistent with a rapid progression of pre-existing limited scleroderma with the development of new rheumatological symptoms, including vasculitis. We propose that this progression was secondary to paraneoplastic stimulation by the renal cell carcinoma. Clinicians should consider looking for a malignancy in patients with connective tissue disorders who present with a myriad of new symptoms.
authors: Corresponding Author: Victor Abrich, Marshfield Clinic, Department of Internal Medicine, 1000 North Oak Avenue, Marshfield, WI 54449 USA. abrich.victor@marshfieldclinic.org.
authors: Victor
authors: V
authors: Abrich
authors: Sudhir
authors: S
authors: Duvuru
authors: Howard J
authors: HJ
authors: Swanson
mesh_terms: D000368:Aged; D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D002292:Carcinoma, Renal Cell / Q000000981:diagnostic imaging / Q000188:drug therapy; D005260:Female; D005921:Glomerulonephritis / Q000150:complications / Q000000981:diagnostic imaging / Q000188:drug therapy; D006801:Humans; D007680:Kidney Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy; D008775:Methylprednisolone / Q000008:administration & dosage; D011241:Prednisone / Q000008:administration & dosage; D000069283:Rituximab; D045745:Scleroderma, Limited / Q000150:complications / Q000000981:diagnostic imaging / Q000188:drug therapy; D014057:Tomography, X-Ray Computed
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab; D011241:Prednisone; D008775:Methylprednisolone
keywords: Complications; Connective Tissue Diseases; Etiology; Neoplasms; Pauci-immune crescentic glomerulonephritis; Renal Cell Carcinoma; Scleroderma
references: Rev Urol. 2002 Fall;4(4):163-70
references: 16985675
references: Gerontology. 2011;57(1):3-10
references: 20453490
references: Clin Rheumatol. 2012 Aug;31(8):1273-7
references: 22644090
references: Scand J Rheumatol. 2001;30(4):185-8
references: 11578009
references: Semin Oncol. 1997 Jun;24(3):269-76
references: 9208883
references: Curr Rheumatol Rep. 2010 Feb;12(1):8-18
references: 20425528
references: Pol Arch Med Wewn. 2008 Mar;118(3):119-26
references: 18476458
references: Adv Anat Pathol. 2012 Mar;19(2):111-24
references: 22313839
references: Isr Med Assoc J. 2011 Jan;13(1):14-20
references: 21446230
references: Clin Nephrol. 1993 Jul;40(1):22-5
references: 8358871
references: Br J Dermatol. 2012 Nov;167(5):1067-75
references: 22816490
references: Neurosci Behav Physiol. 2007 Jan;37(1):1-6
references: 17180311
references: Cancer. 1995 Sep 1;76(5):910-4
references: 8625197